Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Bayer Files for Fosrenol for Patients with CKD in Preservation Period
October 5, 2012
- MTPC Outsources All Logistics Operations
October 5, 2012
- Takeda, Lundbeck File NDA for Major Depressive Disorder Treatment Vortioxetine in US
October 4, 2012
- Baxter Files for Approval in Japan for Cell Culture Influenza Vaccine
October 4, 2012
- Takeda Initiates Drug Discovery Collaboration with Advinus of India to Boost Research Productivity
October 4, 2012
- Daiichi Sankyo Discontinues PIII Study of ARQ197 in Patients with NSCLC
October 4, 2012
- Sanofi Takes Over 3 Genzyme Products
October 3, 2012
- Astellas Strikes Deal to License JAK Inhibitor to Janssen Biotech Outside Japan
October 3, 2012
- Seikagaku Completes New Production Facilities for Gel-One to Meet Increasing Demand in US
October 3, 2012
- Shionogi Acquires Worldwide Rights for Cholesterol Absorption Inhibitor from Kotobuki
October 3, 2012
- “Comprehensive Strengths” Have Been Biggest Result of Alliance with Roche: Chairman Nagayama of Chugai
October 3, 2012
- Takeda Receives Approval for Hyperlipidemia Drug Lotriga
October 2, 2012
- Bayer Yakuhin Obtains Approval for VEGF Inhibitor Eylea, Santen to Distribute Product
October 2, 2012
- Sanwa Kagaku, Kowa Obtain Approval for DPP-4 Inhibitor Suiny, to Market Under One Brand Name
October 2, 2012
- Qol Reaches Agreement for Approximately Half of Its Price Negotiations with Wholesalers
October 1, 2012
- Mochida Enters Generic Anticancer Drug Market with Hospira Products
October 1, 2012
- Osaka District Court Rules Against Takeda in Actos Patent Dispute with 8 Generic Drug Makers
October 1, 2012
- Novartis Obtains Approval for COPD Drug Seebri, Copromotion Planned with Eisai
October 1, 2012
- Daiichi Sankyo, AZ to Step Up Promotion for Nexium upon Lifting of Long-Term Prescription Ban
October 1, 2012
- Eisai Shifts Production Management Structure to Unit-Based Structure by Product Portfolio
October 1, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…